whatshot

NNVC   $1.5  15.38% Market Closed After Close 1.55 3.33%

NanoViricides, Inc.
show_chart Advanced Chart of NNVC
Last Events:

2023-08-09 Signal in EMA100 changed from bullish reversal to bearish reversal. The price is trying to cross down the moving average line If the intersection will be successful, then a downside trend can be formed.

2023-08-09 Signal in EMA50 changed from bullish reversal to bearish reversal. The price is trying to cross down the moving average line If the intersection will be successful, then a downside trend can be formed.

2023-08-09 Trend Power changed from strong to almost flat.

2023-08-09 Trend changed from down and flat to turning up.

2023-08-06 Signal in RSI changed from bullish to bearish. RSI indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: exit from the overbought zone.

2023-08-06 Trend Power changed from slow to strong.

2023-08-05 Signal in RSI changed from bearish to bullish. RSI indicator is in the upper part of the neutral territory and it heading north. These factors indicate that positive dynamics is recovering. Last signal: exit from the overbought zone.

2023-08-05 Trend Power changed from almost flat to slow.

Current temperature: 7.61
ST: 0, Cor:

50-50 Year Forecast
Low with % probability:
Target: 1.20
High with % probability:
Analyst Recommendations:
Number of estimates 2
Target Price Mean 6.00
Mean unverified/preliminary 6.00 / 6.00
Target Price Low / High 6.00 / 6.00
Median / STD DEV 6.00 / 0.00
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total Sell Buy ActivelyBuy
rsi Sell Buy ActivelyBuy
macd None None None
stoch None None None
ma20 None Buy None
ma50 None None None
ma100 None Buy None
Candlestick PatternApril 20, 2026 Bearish Belt Hold - is a candlestick that has a long black body and small shadows. It opens on the high of the day. It occurs in a uptrend. Considered to be a bearish reversal pattern.
ISIN US6300873022
ceo Dr. Anil R. Diwan Ph.D.
Website https://www.nanoviricides.com
NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product formulations for the treatment of COVID infections comprising NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form, which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric treatments. It also offers NV-387 Solution for injection, infusion, and inhalation to treat severe cases that are not hospitalized and carried out by an injection; and injectable solution that delivered directly into the lungs as a fog created using portable battery operated nebulizer devices, which enables action at infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia. In addition, the company develops NV-HHV-1, a skin cream for the treatment of Shingles rash, which has completed non-clinical pharmacology studies; oral drug with NV-HHV-1 as the active ingredient for the treatment of HSV-1 cold sores and HSV-2 genital ulcers; and other drug candidates in HIVCide program for the treatment of Dengue and Ebola virus, as well as provides Nanoviricide platform technology to treat various types of viruses. NanoViricides, Inc. was incorporated in 2005 and is headquartered in Shelton, Connecticut.